Roche Ticlid Safety Program Is Promotional, Not Educational, Teva Asserts

Roche's Ticlid (ticlopidine) educational program on the risks of neutropenia and agranulocytosis consists of promotional rather than safety information, Teva Pharmaceuticals maintains in a Jan. 6 letter to FDA.